|
Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - STARTMRK
|
|
|
Reported by Jules Levin
CROI 2010
E. DeJesus1, C. Cohen2, J. Lennox3, A. Lazzarin4, D. Berger5, B. Jin6, H. Teppler6, B-Y. Nguyen6, R. Leavitt6, P. Sklar6 for the STARTMRK (P021) Investigators
1Orlando Immunology Center, Orlando, FL, USA; 2Community Research Initiative of New England, Boston, MA, USA; 3Emory University, Atlanta, GA, USA; 4University Vita-Salute San Raffaele, Milan, Italy; 5Northstar Medical Center, University of Illinois at Chicago, Chicago, IL, USA; 6Merck Research Labs, North Wales, PA, USA
![CROI1.gif](../images/040615/040615-4/CROI1.gif)
![CROI2.gif](../images/040615/040615-4/CROI2.gif)
![CROI3.gif](../images/040615/040615-4/CROI3.gif)
![CROI4.gif](../images/040615/040615-4/CROI4.gif)
![CROI5.gif](../images/040615/040615-4/CROI5.gif)
![CROI6.gif](../images/040615/040615-4/CROI6.gif)
![CROI7.gif](../images/040615/040615-4/CROI7.gif)
![CROI8.gif](../images/040615/040615-4/CROI8.gif)
![CROI9.gif](../images/040615/040615-4/CROI9.gif)
![CROI10.gif](../images/040615/040615-4/CROI10.gif)
![CROI11.gif](../images/040615/040615-4/CROI11.gif)
![CROI12.gif](../images/040615/040615-4/CROI12.gif)
![CROI13.gif](../images/040615/040615-4/CROI13.gif)
|
|
|
|
|
|
|